EZH2 Y641 mutations in follicular lymphoma-Reference-Cited by-同舟云学术

EZH2 Y641 mutations in follicular lymphoma

Published:2011-01-14 Issue:4 Volume:25 Page:726-729
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bödör C,O'Riain C,Wrench D,Matthews J,Iyengar S,Tayyib H,Calaminici M,Clear A,Iqbal S,Quentmeier H,Drexler H G,Montoto S,Lister A T,Gribben J G,Matolcsy A,Fitzgibbon J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010311.pdf

Reference14 articles.

1. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–185.

2. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247–5255.

3. O’Riain C, O’Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia 2009; 23: 1858–1866.

4. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722–726.

5. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665–667.

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation;Cell Reports;2024-09

2. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition;Nature Communications;2024-04-24

3. Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation;2024-04-10

4. EZH2-mediated development of therapeutic resistance in cancer;Cancer Letters;2024-04

5. EZH2 as a potential therapeutic target for gastrointestinal cancers;Pathology - Research and Practice;2024-01